Ceruloplasmin replacement therapy ameliorates neurological symptoms in a preclinical model of aceruloplasminemia

A Zanardi, A Conti, M Cremonesi, P D'Adamo, Maria Enrica Gilberti, P Apostoli, CV Cannistraci, Alberto Piperno, Samuel David, M Alessio

Research output: Contribution to journalArticle

Abstract

Aceruloplasminemia is a monogenic disease caused by mutations in the ceruloplasmin gene that result in loss of protein ferroxidase activity. Ceruloplasmin plays a role in iron homeostasis, and its activity impairment leads to iron accumulation in liver, pancreas, and brain. Iron deposition promotes diabetes, retinal degeneration, and progressive neurodegeneration. Current therapies mainly based on iron chelation, partially control systemic iron deposition but are ineffective on neurodegeneration. We investigated the potential of ceruloplasmin replacement therapy in reducing the neurological pathology in the ceruloplasmin-knockout (CpKO) mouse model of aceruloplasminemia. CpKO mice were intraperitoneal administered for 2 months with human ceruloplasmin that was able to enter the brain inducing replacement of the protein levels and rescue of ferroxidase activity. Ceruloplasmin-treated mice showed amelioration of motor incoordination that was associated with diminished loss of Purkinje neurons and reduced brain iron deposition, in particular in the choroid plexus. Computational analysis showed that ceruloplasmin-treated CpKO mice share a similar pattern with wild-type animals, highlighting the efficacy of the therapy. These data suggest that enzyme replacement therapy may be a promising strategy for the treatment of aceruloplasminemia.
Original languageEnglish
Pages (from-to)91-106
Number of pages16
JournalEMBO Molecular Medicine
Volume10
Issue number1
Publication statusPublished - 2018

    Fingerprint

Cite this

Zanardi, A., Conti, A., Cremonesi, M., D'Adamo, P., Gilberti, M. E., Apostoli, P., Cannistraci, CV., Piperno, A., David, S., & Alessio, M. (2018). Ceruloplasmin replacement therapy ameliorates neurological symptoms in a preclinical model of aceruloplasminemia. EMBO Molecular Medicine, 10(1), 91-106.